Work

Optimizing the Natalizumab Dose Interval to Reduce PML Risk- Lessons from the Pharmacokinetics of Therapy Discontinuation (P4.032)

Year: 2015

Type: article

Source: Neurology

DOI: 10.1212/wnl.84.14_supplement.p4.032

Authors: John Foley, Ryan Metzger, Tamara Hoyt, Angelene Christensen

Language: English

Topic: Polyomavirus and related diseases

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W652920478

FWCI: 0.146

Cites:

Cited by: 1

Related to: 10